ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages iRhythm Technologies, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IRTC

New York, March 16, 2024 /PRNewswire/ —

WHY:

Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of iRhythm Technologies, Inc. (NASDAQ: IRTC) between January 11, 2022 and May 30, 2023, both dates inclusive (the “Class Period”), of the important April 8, 2024 lead plaintiff deadline.

SO WHAT:

If you purchased iRhythm Technologies, Inc. common stock during the Class Period mentioned, you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement with the firm.

The lawsuit alleges that iRhythm made materially false and/or misleading statements and/or failed to disclose that: (1) iRhythm’s business and sales practices were based on a purported internal coding error which could result in increased reimbursements from Medicare and other payors; and (2) iRhythm’s revenues were boosted by lawsuits brought against Medicare providers under the False Claims Act.

Rosen Law Firm encourages all iRhythm investors, or anyone with questions about this lawsuit or seeking guidance on their rights and potential claims, to contact or visit the firm’s website.

How this will affect me:

If you are an investor who purchased iRhythm Technologies, Inc. common stock during the Class Period, this lawsuit could have a significant impact on your investment. It is important to seek legal counsel before the April 8, 2024 lead plaintiff deadline to secure your rights and potential compensation.

How this will affect the world:

The outcome of this securities class action against iRhythm Technologies, Inc. could set a precedent for how companies are held accountable for misleading statements and business practices. It may lead to increased transparency and scrutiny in the healthcare industry, particularly regarding reimbursement practices and revenue sources.

Conclusion:

It is crucial for investors who purchased iRhythm Technologies, Inc. common stock during the Class Period to take action before the April 8, 2024 lead plaintiff deadline. By securing legal counsel, investors can protect their rights and potentially recover compensation for any losses incurred. Additionally, the outcome of this lawsuit could have broader implications for the healthcare industry and investor rights as a whole.